No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 14 of the 30 quarters in the window, leaving 16 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 18.2x · 10Y median 41.7x · 14th percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 31
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T11:10:57.771Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for BridgeBio Pharma, Inc. (BBIO) stock was $66.14 as of Oct 5, 2026, 4:00 PM EDT, down 1.65% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +25.0% · 3-year avg +39.0%/yr · 5-year avg +7.4%/yr
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions.
Biotechnology · Palo Alto, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Oct 28, 2026
22 days away
EPS Estimate
-0.61
Revenue Est.
$269.01M
Last Quarter Results
EPS
$-0.78
vs Estimate
$-0.58
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1BBIO | $12.95B | $66.14 | -1.65% | +24.99% | +7.38% | N/A | N/A |
| 2ICLR | $12.89B | $168.33 | +3.88% | -13.12% | -8.50% | +8.07% | vs BBIO |
| 3CORT | $13.19B | $122.03 | +4.99% | +38.22% | +43.90% | +33.70% | vs BBIO |
| 4BAX | $12.52B | $24.22 | +3.11% | +1.70% | -19.87% | -5.15% | vs BBIO |
| 5PEN | $12.49B | $317.11 | -0.14% | +23.72% | +4.16% | +15.63% | vs BBIO |
| 6BTSG | $12.17B | $62.00 | +2.90% | +117.80% | N/A | N/A | vs BBIO |
forward FY estimate
N/A
$243.68M
vs Estimate
$220.91M
Consensus Rating
Based on 21 analysts
Average Price Target
$109.10
+64.9% upside
Low
$80.00
Current
$66.14
High
$157.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.82 | $-0.61 | $-0.37 | 7 |
| Quarter ending Dec 2026 | $-0.76 | $-0.43 | $0.12 | 7 |
| Quarter ending Mar 2027 | $-0.34 | $-0.26 | $-0.21 | 2 |
| Quarter ending Jun 2027 | $-0.23 | $-0.18 | $-0.14 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-3.54 | $-2.79 | $-1.98 | 12 |
| FY 2027 | $-0.26 | $0.06 | $0.33 | 12 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $253.38M | $269.01M | $284.03M | 11 |
| Quarter ending Dec 2026 | $264.97M | $314.83M | $384.73M | 11 |
| Quarter ending Mar 2027 | $279.49M | $327.98M | $405.82M | 5 |
| Quarter ending Jun 2027 | $321.19M | $376.92M | $466.37M | 5 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $955.88M | $1.02B | $1.11B | 15 |
| FY 2027 | $1.47B | $1.68B | $1.87B | 14 |
